17.4 C
New York
Tuesday, June 9, 2026

Tag: allergy

newssourceFORcompanyinformationcontent1marketreleases

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion...

Châtillon, France, le 8 juin (22 :30 CET) 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 5, 2026

Allergy & Asthma Network Statement on Centers for Medicare & Medicaid Services Work Requirements Interim Final Rule

FAIRFAX, Va., June 4, 2026 /PRNewswire/ -- Allergy & Asthma Network CEO Lynda Mitchell issued the following statement in response to the Centers for Medicare & Medicaid Services...

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with...

Châtillon, France, June 2, 2026

HelloNation Article Explains Protecting Eyes From Kentucky Allergies Featuring Optometry Expert Dr. Kimberly Arnett

The article clarifies how to distinguish allergy symptoms from infections and outlines steps to reduce irritation and protect eye health.FLORENCE, Ky., June 2, 2026...

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

EAACI 於 2025 年 EAACI 大會 (EAACI Congress 2025）上啟動全球抗生素過敏意識宣傳活動

蘇黎世, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI 於格拉斯哥舉行的 2025 年度大會上啟動了抗生素過敏意識宣傳活動。 此倡議開創了一項全球行動，以解決錯誤標籤問題及其與抗微生物劑耐藥性 (AMR) 的關聯。

L’EAACI lance une campagne mondiale de sensibilisation aux allergies aux antibiotiques lors du EAACI Congress 2025

ZURICH, 15 août 2025 (GLOBE NEWSWIRE) -- L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 à Glasgow. Cette initiative marque le début d’un effort mondial visant à lutter contre les erreurs d’étiquetage et son lien avec la résistance aux antimicrobiens (RAM).

EAACI 在 EAACI 2025 年大会 (EAACI Congress 2025) 上启动全球抗生素过敏意识宣传活动

苏黎世, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI 在其 2025 年格拉斯哥大会期间启动了抗生素过敏意识宣传活动。 这一倡议开启了一项全球行动，旨在解决误标问题及其与抗菌素耐药性 (AMR) 的关联。

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAllergy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers